Expression, purification, and characterization of mouse CYP2D22

Drug Metabolism and Disposition

Volumn 34, Issue 7, 2006, Pages 1167-1174

  Yu, Ai Ming ^a,b   Haining, Robert L ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYTOCHROME P450 2D; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 D22; DEXTROMETHORPHAN; KETOCONAZOLE; METHADONE; QUINIDINE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; DRUG INHIBITION; DRUG MECHANISM; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PURIFICATION; ENZYME SPECIFICITY; HUMAN; KINETICS; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMINO ACID SEQUENCE; ANIMALS; BACULOVIRIDAE; CELL LINE; CLONING, MOLECULAR; CODEINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DEXTROMETHORPHAN; ENZYME INHIBITORS; FLUOXETINE; INSECTS; KETOCONAZOLE; KINETICS; METHADONE; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; QUINIDINE; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

ANIMALIA; INSECTA;

EID: 33745245269     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008870     Document Type: Article

References (55)

1. Adams M, Lennard MS, Otton SV, Tucker GT, and Woods HF (1991) Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type. Biochem Pharmacol 42:947-949.
2. Al-Dabbagh SG, Idle JR, and Smith RL (1981) Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 33:161-164.
3. Amet Y, Berthou F, Fournier G, Dreano Y, Bardou L, Cledes J, and Menez JF (1997) Cytochrome P450 4A and 2E1 expression in human kidney microsomes. Biochem Pharmacol 53:765-771.
4. Barham HM, Lennard MS, and Tucker GT (1994) An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem Pharmacol 47:1295-1307.
5. Blume N, Leonard J, Xu ZJ, Watanabe O, Remotti H, and Fishman J (2000) Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch Biochem Biophys 381:191-204.
6. Caraco Y, Tateishi T, Guengerich FP, and Wood AJ (1996) Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos 24:761-764.
7. Ducharme J, Abdullah S, and Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678:113-128.
8. Fonne P-R, Bargetzi MJ, and Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148:1144-1150.
9. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, and Wolf CR (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111-125.
10. Gonzalez FJ and Idle JR (1994) Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 26:59-70.
11. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewka J, Kozak CA, Gillette J, Gelboin HV, and Hardwick JP (1987) Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping and molecular analysis of the DA rat polymorphism. DNA 6:149-161.
12. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, and Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond) 331:442-446.
13. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
14. Haining R and Yu A (2003) Cytochrome P450 pharmacogenetics, in Cytochrome P450 and Drug Metabolism (Lee J ed), pp 343-387, FontisMedia, Lausanne, Switzerland.
15. Haining RL, Hunter AP, Veronese ME, Trager WF, and Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458.
16. Hedlund E, Gustafsson JA, and Warner M (1998) Cytochrome P450 in the brain: 2B or not 2B. Trends Pharmacol Sci 19:82-85.
17. Hiroi T, Imaoka S, and Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838-843.
18. Hosseinpour F and Wikvall K (2000) Porcine microsomal vitamin D(3) 25-hydroxylase (CYP2D25). Catalytic properties, tissue distribution and comparison with human CYP2D6. J Biol Chem 275:34650-34655.
19. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, and Menez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365-373.
20. Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, and Hall SD (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374-384.
21. Kahn GC, Rubenfield M, Davies DS, Murray S, and Boobis AR (1985) Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metab Dispos 13:510-516.
22. Kawashima H, Sequeira DJ, Nelson DR, and Strobel HW (1996) Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine Ndemethylation. J Biol Chem 271:28176-28180.
23. Kimura S, Umeno M, Skoda RC, Meyer UA, and Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 45:889-904.
24. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, and Schwartz JB (1999) In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan and verapamil. Clin Pharmacol Ther 66:40-50.
25. Lofgren S, Hagbjork AL, Ekman S, Fransson-Steen R, and Terelius Y (2004) Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 34:811-834.
26. Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, and Lawton MP (1999) Molecular cloning, expression and characterization of CYP2D17 from cynomolgus monkey liver. Arch Biochem Biophys 372:189-196.
27. Masubuchi Y, Iwasa T, Hosokawa S, Suzuki T, Horie T, Imaoka S, Funae Y, and Narimatsu S (1997) Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther 282:1435-1441.
28. Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, and Gonzalez FJ (1989) The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28:7349-7355.
29. McCann SJ, Pond SM, James KM, and Le Couteur DG (1997) The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 153:50-53.
30. Moody DE, Alburges ME, Parker RJ, Collins JM, and Strong JM (1997) The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), nor-LAAM, and methadone. Drug Metab Dispos 25:1347-1353.
31. Nebert DW (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60:265-271.
32. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
33. Norman TR, Gupta RK, Burrows GD, Parker G, and Judd FK (1993) Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 8:25-29.
34. Oda Y and Kharasch ED (2001) Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 298:1021-1032.
35. Ohta S, Tachikawa O, Makino Y, Tasaki Y, and Hirobe M (1990) Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 46:599-605.
36. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
37. O'Reilly DR, Miller LK, and Luckow VA (1994) Baculovirus Expression Vectors - A Laboratory Manual. Oxford University Press, New York.
38. Ortiz de Montellano PR (1995) Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum Press, London.
39. Peters WH, Nagengast FM, and van Tongeren JH (1989) Glutathione S-transferase, cytochrome P450 and uridine 5′-diphosphate- glucuronosyltransferase in human small intestine and liver. Gastroenterology 96:783-789.
40. Pierce TL, Murray AG, and Hope W (1992) Determination of methadone and its metabolites by high performance liquid chromatography following solid-phase extraction in rat plasma. J Chromatogr Sci 30:443-447.
41. Purdon MP and Lehman-McKeeman LD (1997) Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods 37:67-73.
42. Saitoh T, Xia Y, Chen X, Masliah E, Galasko D, Shults C, Thal LJ, Hansen LA, and Katzman R (1995) The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 37:110-112.
43. Sambrook J, Fritsch EF, and Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
44. Shen AL, Christensen MJ, and Kasper CB (1991) NADPH-cytochrome P-450 oxidoreductase. The role of cysteine 566 in catalysis and cofactor binding. J Biol Chem 266:19976-19980.
45. Siegle I, Fritz P, Eckhardt K, Zanger UM, and Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245.
46. Skoda RC, Gonzalez FJ, Demierre A, and Meyer UA (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-5243.
47. Thompson CM, Capdevila JH, and Strobel HW (2000) Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther 294:1120-1130.
48. Venn RF and Michalkiewicz A (1990) Fast reliable assay for morphine and its metabolites using high-performance liquid chromatography and native fluorescence detection. J Chromatogr 525:379-388.
49. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, and Baumann P (2000) Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 855:235-243.
50. Wolkenstein P, Tan C, Lecoeur S, Wechsler J, Garcia-Martin N, Charue D, Bagot M, and Beaune P (1998) Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem-Biol Interact 113:39-50.
51. Yu A, Dong H, Lang D, and Haining RL (2001) Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362-1365.
52. Yu A and Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520.
53. Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10 and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291-1300.
54. Yu AM, Idle JR, Herraiz T, Kupfer A, and Gonzalez FJ (2003) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319.
55. Yue QY and Sawe J (1997) Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 52:41-47.